WallStreetZenWallStreetZen

NASDAQ: AGIO
Agios Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Agios Pharmaceuticals earnings were $650.1M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest AGIO earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$112.0M, up 25.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AGIO reported annual earnings of $673.7M, with -291.4% growth. The next AGIO earnings date is Oct 30, 2025.

AGIO past earnings growth

How has AGIO's earnings growth performed historically?

Company
N/A
Industry
30.11%
Market
34.43%
AGIO's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
AGIO's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

AGIO earnings history

Current Revenue
$40.9M
Current Earnings
$650.1M
Current Profit Margin
1,590.4%

AGIO Return on Equity

Current Company
43.3%
Current Industry
-10%
Current Market
30.7%
AGIO's Return on Equity (43.3%)... subscribe to Premium to read more.
High Return on Equity Performance

AGIO undefined

Current Company
40.1%
Current Industry
-0.2%
AGIO is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when AGIO announces earnings.

AGIO undefined

Current Company
49.57%
Current Industry
6.4%
AGIO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AGIO vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
AGIO$711.54M$650.08M-15.73%$11.45
IDYA-$327.78M-$331.80MN/A-$3.85
GLPGN/AN/AN/AN/A
RXRX-$562.99M-$649.13MN/A-$1.82
TVTX-$107.71M-$169.06MN/A-$2.02
View Top Biotech Stocks

AGIO earnings dates

Next earnings date
Oct 30, 2025

Agios Pharmaceuticals Earnings Reports & History FAQ

What were Agios Pharmaceuticals's earnings last quarter?

On AGIO's earnings call on Invalid Date, Agios Pharmaceuticals (NASDAQ: AGIO) reported Q2 2025 earnings per share (EPS) of -$1.93, up 14.2% year over year. Total AGIO earnings for the quarter were -$112.02 million. In the same quarter last year, Agios Pharmaceuticals's earnings per share (EPS) was -$1.69.

If you're new to stock investing, here's how to buy Agios Pharmaceuticals stock.

When does Agios Pharmaceuticals report earnings?

The next AGIO earnings call is Invalid Date. Add AGIO to your watchlist to be reminded of Agios Pharmaceuticals's next earnings date.

Is Agios Pharmaceuticals profitable or losing money?

As of the last Agios Pharmaceuticals earnings report, Agios Pharmaceuticals is currently profitable. Agios Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $650.08 million, a 278.14% decrease year over year.

What was AGIO's earnings growth in the past year?

As of Agios Pharmaceuticals's earnings date in Invalid Date, Agios Pharmaceuticals's earnings has grown year over year. AGIO earnings in the past year totalled $650.08 million.

What are Agios Pharmaceuticals's earnings expectations?

The current EPS estimate for Agios Pharmaceuticals's earnings report in Invalid Date is -$1.91.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.